A delay, as opposed to a firm stagnation, then, but one unfolding over several years. This applies not only to SMEs, but to big pharma, too, in terms of restructuring and refocusing – even in terms of ...

A new report from WeCount confirms what’s becoming increasingly clear: Abortion in the U.S. is not going away. It’s changing ...

The FDA approved Lynozyfic for relapsed multiple myeloma, but serious risks require restricted use under a special safety program.

A group of 53 biotech leaders are expressing their support for mifepristone in a letter to the Food and Drug Administration, ...

Regeneron Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for ...